Document:

Exhibit 10.6

 

Execution Version

 

ORION BIOTECH OPPORTUNITIES CORP.

645 Fifth Avenue, 21st Floor

New York, New
York 10022

 

May 12, 2021

 

Orion Sponsor Holdings, LLC

645 Fifth Avenue, 21st Floor

New York, New York 10022

 

Ladies and Gentlemen:

 

This letter will confirm our
agreement that, commencing on the effective date (the “Effective Date”) of the registration statement (the “Registration
Statement”) for the initial public offering (the “IPO”) of the securities of Orion Biotech Opportunities
Corp. (the “Company”) and continuing until the earlier of (i) the consummation by the Company of an initial
business combination and (ii) the Company’s liquidation (in each case as described in the Registration Statement) (such earlier
date hereinafter referred to as the “Termination Date”), Orion Sponsor Holdings, LLC (the “Sponsor”)
shall take steps directly or indirectly to make available to the Company certain office space, and administrative and other services as
may be required by the Company from time to time, situated at 645 Fifth Avenue, 21st Floor, New York, New York 10022 (or any successor
location). In exchange therefor, the Company shall pay the Sponsor a sum of up to $10,000 per month commencing on the Effective Date and
continuing monthly thereafter until the Termination Date. The Sponsor hereby agrees that it does not have any right, title, interest or
claim of any kind (a “Claim”) in or to any monies that may be set aside in a trust account (the “Trust
Account”) that may be established in connection with and upon the consummation of the IPO and hereby irrevocably waives
any Claim it presently has or may have in the future as a result of, or arising out of, any negotiations, contracts or agreements with
the Company and will not seek recourse, reimbursement, payment or satisfaction of any Claim against the Trust Account or any monies or
other assets in the Trust Account for any reason whatsoever.

 

This letter agreement constitutes
the entire agreement and understanding of the parties hereto in respect of its subject matter and supersedes all prior understandings,
agreements, or representations by or among the parties hereto, written or oral, to the extent they relate in any way to the subject matter
hereof or the transactions contemplated hereby.

 

This letter agreement may
not be amended, modified or waived as to any particular provision, except by a written instrument executed by the parties hereto.

 

The parties may not assign
this letter agreement and any of their rights, interests, or obligations hereunder without the consent of the other party. Any purported
assignment in violation of this paragraph shall be void and ineffectual and shall not operate to transfer or assign any interest or title
to the purported assignee.

 

This letter agreement shall
be governed by, construed in accordance with, and interpreted pursuant to the laws of the State of New York, without giving effect to
its choice of laws principles that will apply the laws of another jurisdiction.

 

This letter agreement may
be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall
constitute one and the same agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be
produced to evidence the existence of this letter agreement.

 

[Signature Page Follows]

 

     

     

    

  

	 	Very truly yours,
	 	 
	 	ORION BIOTECH OPPORTUNITIES CORP.
	 	 	 
	 	By:	/s/ Mark Kayal
	 	Name:	Mark Kayal
	 	Title:	Chief Financial Officer and Secretary

 

	AGREED TO AND ACCEPTED BY:	 
	 	 
	ORION SPONSOR HOLDINGS, LLC	 
	 	 	 
	By:	/s/ Marcello Liguori	 
	Name: 	Marcello Liguori	 
	Title:	Member	 

 

[Signature Page to Administrative Services Agreement]Exhibit 10.7

 

Execution Version

 

FORWARD PURCHASE AGREEMENT

 

This Forward Purchase Agreement
(this “Agreement”) is entered into as of May 12, 2021, by and between Orion Biotech Opportunities Corp.,
a Cayman Islands exempted company (the “Company”), and the party listed as the purchaser on the signature
page hereof (the “Purchaser”).

 

WHEREAS, the Company was incorporated
for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination
with one or more businesses (a “Business Combination”);

 

WHEREAS, the Company has filed
with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form S-1 (the
“Registration Statement”) for its initial public offering (“IPO”) of
units (the “Units”) at a price of $10.00 per Unit, each comprised of one Class A ordinary share of the
Company, par value $0.0001 per share (the “Ordinary Share(s)”), and one-fifth of one redeemable warrant,
where each whole redeemable warrant is exercisable to purchase one Ordinary Share at an exercise price of $11.50 per share (the “Warrant(s)”);

 

WHEREAS, following the closing
of the IPO (the “IPO Closing”), the Company will seek to identify and consummate a Business Combination;
and

 

WHEREAS, the parties wish
to enter into this Agreement, pursuant to which immediately prior to the closing of the Company’s initial Business Combination (the
“Business Combination Closing”), the Company shall issue and sell, and the Purchaser shall purchase,
on a private placement basis, up to $20,000,000 of units, at a price of $10.00 per unit, each comprised of one Ordinary Share (the “Forward
Purchase Shares”) and one-fifth of one warrant to purchase one Ordinary Share at an exercise price of $11.50 (the “Forward
Purchase Warrants” and, together with the Forward Purchase Shares, the “Forward Purchase Securities”)
on the terms and conditions set forth herein.

 

NOW, THEREFORE, in consideration
of the premises, representations, warranties and the mutual covenants contained in this Agreement, and for other good and valuable consideration,
the receipt, sufficiency and adequacy of which are hereby acknowledged, the parties hereto agree as follows:

 

1. Sale
and Purchase.

 

(a) Forward
Purchase Securities.

 

(i) The
Company shall issue and sell to the Purchaser, and the Purchaser shall purchase from the Company, (1) the number of Forward Purchase Shares
that is the quotient of (x) the amount of capital committed to the Purchaser and allocated to this Agreement as notified by the Purchaser
to the Company no later than five (5) Business Days prior to such time as any definitive agreement with respect to a Business Combination
is executed by the Company (the “Allocation Notice”), which amount shall be no more than $20,000,000
in the Purchaser’s sole discretion, and (y) $10.00 (the “Number of Forward Purchase Shares”), plus
(2) the number of Forward Purchase Warrants which is the product of (x) the number of Forward Purchase Shares as determined by clause
(1) and (y) 1/5 (the “Number of Forward Purchase Warrants”) for an aggregate purchase price of $10.00
multiplied by the number of Forward Purchase Shares issued and sold hereunder (the “FPS Purchase Price”).
No fractional Forward Purchase Warrants will be issued.

 

     

     

    

  

(ii) Each
Forward Purchase Warrant will have the same terms as the Company’s private placement warrants, purchased by Orion Sponsor Holdings,
LLC in a private placement occurring simultaneously with the closing of the IPO, and will be subject to the terms and conditions of the
Warrant Agreement to be entered into between the Company and Continental Stock Transfer & Trust Company, as Warrant Agent, in
connection with the IPO (the “Warrant Agreement”). Each Forward Purchase Warrant will entitle the holder
thereof to purchase one Ordinary Share at a price of $11.50 per share, subject to adjustment as described in the Warrant Agreement and
only whole Forward Purchase Warrants will be exercisable. The Forward Purchase Warrants will become exercisable on the later of thirty
(30) days after the Business Combination Closing and twelve (12) months from the IPO Closing, and will expire five years after the Business
Combination Closing or earlier upon redemption or the liquidation of the Company, as described in the Warrant Agreement.

 

(iii) The
Company shall deliver written notice to the Purchaser as early as practicable, and in any case at least eleven (11) Business Days before
the funding of the FPS Purchase Price to the Escrow Account (defined below), specifying the anticipated date of the Business Combination
Closing, the aggregate FPS Purchase Price and instructions for wiring the FPS Purchase Price to an account (the “Escrow
Account”) of a third-party escrow agent, which shall be the Company’s transfer agent (the “Escrow
Agent”), pursuant to an escrow agreement between the Company and the Escrow Agent (the “Escrow Agreement”).
Two (2) Business Days before the anticipated date of the Business Combination Closing specified in such written notice, the Purchaser
shall deliver the FPS Purchase Price in cash via wire transfer to the account specified in such written notice, to be held in escrow pending
the Business Combination Closing. If the Business Combination Closing does not occur within thirty (30) days after the Purchaser delivers
the FPS Purchase Price to the Escrow Agent, the Escrow Agreement will provide that the Escrow Agent shall automatically return to the
Purchaser the FPS Purchase Price; provided that the return of the FPS Purchase Price placed in escrow shall not terminate the Agreement
or otherwise relieve either party of any of its obligations hereunder. The Purchaser agrees that it shall cooperate in good faith and
use reasonable best efforts to effect the funding of the FPS Purchase Price on such notice as necessary to facilitate the consummation
of the proposed Business Combination. For the purposes of this Agreement, “Business Day” means any day,
other than a Saturday or a Sunday, that is neither a legal holiday nor a day on which banking institutions are generally authorized or
required by law or regulation to close in the City of New York, New York.

 

(iv) The
closing of the sale of the Forward Purchase Securities (the “FPS Closing”) shall be held on the same
date as, and immediately prior to, the Business Combination Closing (such date being referred to as the “Closing Date”).
At the FPS Closing, the Company will issue to the Purchaser the Forward Purchase Securities, registered in the name of the Purchaser,
against (and concurrently with) release of the FPS Purchase Price by the Escrow Agent to the Company.

 

    	 	2	 

     

    

  

(b) Delivery of Forward
Purchase Securities.

  

(i) The
Company shall register the Purchaser as the owner of the Forward Purchase Securities purchased by the Purchaser hereunder in the register
of members of the Company (in respect of the Ordinary Shares) and with the Company’s transfer agent by book entry on or promptly
after (but in no event more than two (2) Business Days after) the date of the FPS Closing.

 

(ii) Each
register and book entry for the Forward Purchase Securities purchased by the Purchaser hereunder shall contain a notation, and each certificate
(if any) evidencing the Forward Purchase Securities shall be stamped or otherwise imprinted with a legend, in substantially the following
form:

 

“THE SECURITIES REPRESENTED HEREBY
HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION,
AND MAY NOT BE TRANSFERRED IN VIOLATION OF SUCH ACT AND LAWS.”

 

(c) Legend Removal.
If the Forward Purchase Securities are eligible to be sold without restriction under Rule 144 under the Securities Act of 1933, as amended
(the “Securities Act”), then at the Purchaser’s request in connection with a sale of such Forward
Purchase Securities, the Company will, at its sole expense, cause the Company’s transfer agent to remove the legend set forth in
Section 1(b)(ii) hereof. In connection therewith, if required by the Company’s transfer agent, the Company will promptly cause
an opinion of counsel to be delivered to and maintained with its transfer agent, together with any other authorizations, certificates
and directions required by the transfer agent, that authorize and direct the transfer agent to transfer such Forward Purchase Securities
without any such legend; provided, however, that the Company will not be required to deliver any such opinion, authorization
or certificate or direction if it reasonably believes that removal of the legend could reasonably be expected to result in or facilitate
transfers of Forward Purchase Securities in violation of applicable law.

 

(d) Registration Rights.
The Purchaser shall have registration rights with respect to the Forward Purchase Securities as set forth on Exhibit A (the “Registration
Rights”).

 

2. Representations
and Warranties of the Purchaser. The Purchaser represents and warrants to the Company
as follows, as of the date hereof:

 

(a) Organization and
Power. The Purchaser is duly organized, validly existing, and in good standing under the laws of the jurisdiction of its formation
(if the concept of “good standing” is a recognized concept in such jurisdiction) and has all requisite power and authority
to carry on its business as presently conducted and as proposed to be conducted.

 

    	 	3	 

     

    

 

(b) Authorization.
The Purchaser has full power and authority to enter into this Agreement. This Agreement, when executed and delivered by the Purchaser,
will constitute the valid and legally binding obligation of the Purchaser, enforceable in accordance with its terms, except (i) as limited
by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance and any other laws of general application affecting
enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive
relief or other equitable remedies, or (iii) to the extent the indemnification provisions contained in the Registration Rights may be
limited by applicable federal or state securities laws.

 

(c) Governmental Consents
and Filings. No consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing
with, any federal, state or local governmental authority is required on the part of the Purchaser in connection with the consummation
of the transactions contemplated by this Agreement.

 

(d) Compliance with
Other Instruments. The execution, delivery and performance by the Purchaser of this Agreement and the consummation by the Purchaser
of the transactions contemplated by this Agreement will not result in any violation or default (i) of any provisions of its organizational
documents, if applicable, (ii) of any instrument, judgment, order, writ or decree to which it is a party or by which it is bound, (iii)
under any note, indenture or mortgage to which it is a party or by which it is bound, (iv) under any lease, agreement, contract or purchase
order to which it is a party or by which it is bound or (v) of any provision of federal or state statute, rule or regulation applicable
to the Purchaser, in each case (other than clause (i)), which would have a material adverse effect on the Purchaser or its ability to
consummate the transactions contemplated by this Agreement.

 

(e) Purchase Entirely
for Own Account. This Agreement is made with the Purchaser in reliance upon the Purchaser’s representation to the Company,
which by the Purchaser’s execution of this Agreement, the Purchaser hereby confirms, that the Forward Purchase Securities to be
acquired by the Purchaser will be acquired for investment for the Purchaser’s own account, not as a nominee or agent, and not with
a view to the resale or distribution of any part thereof, and that the Purchaser has no present intention of selling, granting any participation
in, or otherwise distributing the same in violation of law. By executing this Agreement, the Purchaser further represents that the Purchaser
does not presently have any contract, undertaking, agreement or arrangement with any Person to sell, transfer or grant participations
to such Person or to any third Person, with respect to any of the Forward Purchase Securities. If the Purchaser was formed for the specific
purpose of acquiring the Forward Purchase Securities, each of its equity owners is an accredited investor as defined in Rule 501(a) of
Regulation D promulgated under the Securities Act. For purposes of this Agreement, “Person” means an individual,
a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity
or any government or any department or agency thereof.

 

(f) Disclosure of Information.
The Purchaser has had an opportunity to discuss the Company’s business, management, financial affairs and the terms and conditions
of the offering and sale of the Forward Purchase Securities, as well as the terms of the IPO, with the Company’s management.

 

    	 	4	 

     

    

  

(g) Restricted Securities.
The Purchaser understands that the offer and sale of the Forward Purchase Securities to the Purchaser has not been, and will not be,
registered under the Securities Act, by reason of a specific exemption from the registration provisions of the Securities Act that depends
upon, among other things, the bona fide nature of the investment intent and the accuracy of the Purchaser’s representations as
expressed herein. The Purchaser understands that the Forward Purchase Securities are “restricted securities” under applicable
U.S. federal and state securities laws and that, pursuant to these laws, the Purchaser must hold the Forward Purchase Securities indefinitely
unless they are registered with the SEC and qualified by state authorities, or an exemption from such registration and qualification
requirements is available. The Purchaser acknowledges that the Company has no obligation to register or qualify the Forward Purchase
Securities, or any Ordinary Shares that the Forward Purchase Securities may be converted into or exercised for, for resale, except pursuant
to the Registration Rights. The Purchaser further acknowledges that if an exemption from registration or qualification is available,
it may be conditioned on various requirements including, but not limited to, the time and manner of sale, the holding period for the
Forward Purchase Securities, and requirements relating to the Company that are outside of the Purchaser’s control, and which the
Company is under no obligation and may not be able to satisfy. The Purchaser acknowledges that the Company filed the Registration Statement
for the IPO with the SEC. The Purchaser understands that the offering of the Forward Purchase Securities hereunder is not, and is not
intended to be, part of the IPO, and that the Purchaser will not be able to rely on the protection of Section 11 of the Securities Act
with respect to such offering of the Forward Purchase Securities.

 

(h) No Public Market.
The Purchaser understands that no public market now exists for the Forward Purchase Securities, and that the Company has made no assurances
that a public market will ever exist for the Forward Purchase Securities.

 

(i) High Degree of
Risk. The Purchaser understands that its agreement to purchase the Forward Purchase Securities involves a high degree of risk which
could cause the Purchaser to lose all or part of its investment.

 

(j) Accredited Investor.
The Purchaser is an “accredited investor” as defined in Rule 501(a) of Regulation D promulgated under the Securities Act.

 

(k) Foreign Investors.
If the Purchaser is not a United States person (as defined by Section 7701(a)(30) of the U.S. Internal Revenue Code of 1986, as amended),
the Purchaser hereby represents that it has satisfied itself as to the full observance of the laws of its jurisdiction in connection
with any invitation to subscribe for the Forward Purchase Securities or any use of this Agreement, including (i) the legal requirements
within its jurisdiction for the purchase of the Forward Purchase Securities, (ii) any foreign exchange restrictions applicable to such
purchase, (iii) any governmental or other consents that may need to be obtained, and (iv) the income tax and other tax consequences,
if any, that may be relevant to the purchase, holding, redemption, sale, or transfer of the Forward Purchase Securities. The Purchaser’s
subscription and payment for and continued beneficial ownership of the Forward Purchase Securities will not violate any applicable securities
or other laws of the Purchaser’s jurisdiction.

 

(l) No General Solicitation.
Neither the Purchaser, nor any of its officers, directors, employees, agents, stockholders or partners has either directly or indirectly,
including through a broker or finder, (i) to its knowledge, engaged in any general solicitation, or (ii) published any advertisement
in connection with the offer and sale of the Forward Purchase Securities.

 

(m) Residence.
The principal place of business of the Purchaser is the office located at the address of the Purchaser set forth on the signature page
hereof.

 

    	 	5	 

     

    

  

(n) Non-Public Information.
The Purchaser acknowledges its obligations under applicable securities laws with respect to the treatment of material non-public information
relating to the Company.

 

(o) Adequacy of Financing.
The Purchaser has, or will have, from and after receipt of capital commitments not subject to opt-out rights (or for which the party
with such opt-out rights has agreed to fund in respect of this Agreement) in an aggregate amount not less than the FPS Purchase Price,
available to it sufficient funds to satisfy its obligations under this Agreement.

 

(p) Affiliation of
Certain FINRA Members. The Purchaser is neither a person associated nor affiliated with any underwriter of the IPO or, to its actual
knowledge, any other member of the Financial Industry Regulatory Authority (“FINRA”) that is participating
in the IPO.

 

(q) No Other Representations
and Warranties; Non-Reliance. Except for the specific representations and warranties contained in this Section 2 and in any certificate
or agreement delivered pursuant hereto, none of the Purchaser nor any person acting on behalf of the Purchaser nor any of the Purchaser’s
affiliates (the “Purchaser Parties”) has made, makes or shall be deemed to make any other express or
implied representation or warranty with respect to the Purchaser and the offering, sale and purchase of the Forward Purchase Securities,
and the Purchaser Parties disclaim any such representation or warranty. Except for the specific representations and warranties expressly
made by the Company in Section 3 of this Agreement and in any certificate or agreement delivered pursuant hereto, the Purchaser Parties
specifically disclaim that they are relying upon any other representations or warranties that may have been made by the Company, any
person on behalf of the Company or any of the Company’s affiliates (collectively, the “Company Parties”).

 

3. Representations
and Warranties of the Company. The Company represents and warrants to the Purchaser
as follows:

 

(a) Incorporation and
Corporate Power. The Company is an exempted company duly incorporated and validly existing and in good standing under the laws of
the Cayman Islands and has all requisite corporate power and authority to carry on its business as presently conducted and as proposed
to be conducted. The Company has no subsidiaries.

 

(b) Capitalization.
The authorized share capital of the Company consists, as of the date hereof, of:

 

(i) 500,000,000
Ordinary Shares, none of which are issued and outstanding;

 

(ii) 50,000,000
Class B ordinary shares of the Company, par value $0.0001 per share (“Class B Shares”), 5,750,000 of
which are issued and outstanding; and all of the issued and outstanding Class B ordinary shares of the Company have been duly authorized,
are fully paid and nonassessable and were issued in compliance with all applicable laws and the Charter; and

 

    	 	6	 

     

    

  

(iii) 5,000,000
preference shares, none of which are issued and outstanding.

 

(c) Authorization.
All corporate action required to be taken by the Company’s Board of Directors and shareholders in order to authorize the Company
to enter into this Agreement, and to issue the Forward Purchase Securities at the FPS Closing, and the securities issuable upon conversion
or exercise of the Forward Purchase Securities, has been taken or will be taken prior to the FPS Closing, as applicable. All action on
the part of the shareholders, directors and officers of the Company necessary for the execution and delivery of this Agreement, the performance
of all obligations of the Company under this Agreement to be performed as of the FPS Closing, and the issuance and delivery of the Forward
Purchase Securities and the securities issuable upon conversion or exercise of the Forward Purchase Securities has been taken or will
be taken prior to the FPS Closing, as applicable. This Agreement, when executed and delivered by the Company, shall constitute the valid
and legally binding obligation of the Company, enforceable against the Company in accordance with its terms, except (i) as limited by
applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application relating to
or affecting the enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance,
injunctive relief, or other equitable remedies, or (iii) to the extent the indemnification provisions contained in the Registration Rights
may be limited by applicable federal or state securities laws.

 

(d) Valid Issuance
of Forward Purchase Securities.

 

(i) The
Forward Purchase Securities, when issued, sold and delivered in accordance with the terms and for the consideration set forth in this
Agreement and the Charter and registered in the register of members of the Company, and the securities issuable upon conversion or exercise
of the Forward Purchase Securities, when issued in accordance with the terms of the Forward Purchase Securities and this Agreement and
the Charter (in respect of the Forward Purchase Shares), and registered in the register of members of the Company, will be validly issued,
fully paid and nonassessable and free of all preemptive or similar rights, liens, encumbrances and charges with respect to the issue thereof
and restrictions on transfer other than restrictions on transfer specified under this Agreement, applicable state and federal securities
laws and liens or encumbrances created by or imposed by the Purchaser. Assuming the accuracy of the representations of the Purchaser in
this Agreement and subject to the filings described in Section 3(e) below, the Forward Purchase Securities will be issued in compliance
with all applicable federal and state securities laws.

 

(ii) No
“bad actor” disqualifying event described in Rule 506(d)(1)(i)-(viii) of the Securities Act (a “Disqualification
Event”) is applicable to the Company or, to the Company’s knowledge, any Company Covered Person (as defined below),
except for a Disqualification Event as to which Rule 506(d)(2)(ii)—(iv) or (d)(3), is applicable. “Company Covered
Person” means, with respect to the Company as an “issuer” for purposes of Rule 506 promulgated under the
Securities Act, any Person listed in the first paragraph of Rule 506(d)(1).

 

    	 	7	 

     

    

  

(e) Governmental Consents
and Filings. Assuming the accuracy of the representations and warranties made by the Purchaser in this Agreement, no consent, approval,
order or authorization of, or registration, qualification, designation, declaration or filing with, any federal, state or local governmental
authority is required on the part of the Company in connection with the consummation of the transactions contemplated by this Agreement,
except for any filings pursuant to Regulation D of the Securities Act, applicable state securities laws, and pursuant to the Registration
Rights.

 

(f) Compliance with
Other Instruments. The execution, delivery and performance of this Agreement and the consummation of the transactions contemplated
by this Agreement by the Company will not result in any violation or default (i) of any provisions of the Company’s amended and
restated memorandum and articles of association, as they may be amended and/or restated from time to time (the “Articles”),
(ii) of any instrument, judgment, order, writ or decree to which the Company is a party or by which the Company is bound, (iii) under
any note, indenture or mortgage to which the Company is a party or by which the Company is bound, (iv) under any lease, agreement, contract
or purchase order to which the Company is a party or by which the Company is bound or (v) of any provision of federal or state statute,
rule or regulation applicable to the Company, in each case (other than clause (i)) which would have a material adverse effect on the
Company or its ability to consummate the transactions contemplated by this Agreement.

 

(g) Operations.
As of the date hereof, the Company has not conducted, and prior to the IPO Closing the Company will not conduct, any operations other
than organizational activities and activities in connection with the IPO and offering of the Forward Purchase Securities.

 

(h) Foreign Corrupt
Practices. Neither the Company, nor, to the knowledge of the Company, any director, officer, agent, employee or other Person acting
on behalf of the Company has, in the course of its actions for, or on behalf of, the Company (i) used any corporate funds for any unlawful
contribution, gift, entertainment or other unlawful expenses relating to political activity; (ii) made any direct or indirect unlawful
payment to any foreign or domestic government official or employee from corporate funds; (iii) violated or is in violation of any provision
of the U.S. Foreign Corrupt Practices Act of 1977, as amended; or (iv) made any unlawful bribe, rebate, payoff, influence payment, kickback
or other unlawful payment to any foreign or domestic government official or employee.

 

(i) Compliance with
Anti-Money Laundering Laws. The operations of the Company are and have been conducted at all times in compliance with applicable
financial recordkeeping and reporting requirements and all applicable U.S. and non-U.S. anti-money laundering laws, rules and regulations,
including those of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the USA Patriot Act of 2001 and the applicable
money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations
or guidelines, issued, administered or enforced by any governmental agency (collectively, the “Anti-Money Laundering Laws”),
and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company
with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

 

    	 	8	 

     

    

 

(j) Absence of Litigation.
There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory
organization or body pending or, to the knowledge of the Company, threatened against or affecting the Company or any of the Company’s
officers or directors, whether of a civil or criminal nature or otherwise, in their capacities as such.

 

(k) No General Solicitation.
Neither the Company, nor any of its officers, directors, employees, agents or shareholders has either directly or indirectly, including
through a broker or finder, (i) engaged in any general solicitation, or (ii) published any advertisement in connection with the offer
and sale of the Forward Purchase Securities.

 

(l) No Other Representations
and Warranties; Non-Reliance. Except for the specific representations and warranties contained in this Section 3 and in any certificate
or agreement delivered pursuant hereto, none of the Company Parties has made, makes or shall be deemed to make any other express or implied
representation or warranty with respect to the Company, the offering, sale and purchase of the Forward Purchase Securities, the IPO or
a potential Business Combination, and the Company Parties disclaim any such representation or warranty. Except for the specific representations
and warranties expressly made by the Purchaser in Section 2 of this Agreement and in any certificate or agreement delivered pursuant
hereto, the Company Parties specifically disclaim that they are relying upon any other representations or warranties that may have been
made by any of the Purchaser Parties.

 

4. Additional
Agreements, Acknowledgements and Waivers of the Purchaser.

 

(a) Trust Account.

 

(i) The
Purchaser hereby acknowledges that it is aware that the Company will establish a trust account (the “Trust Account”)
for the benefit of its public shareholders upon the IPO Closing. The Purchaser, for itself and its affiliates, hereby agrees that it has
no right, title, interest or claim of any kind in or to any monies held in the Trust Account, or any other asset of the Company as a result
of any liquidation of the Company, except for redemption and liquidation rights, if any, the Purchaser may have in respect of any Ordinary
Shares issued in the IPO (the “Public Shares”) held by it.

 

(ii) The
Purchaser hereby agrees that it shall have no right of set-off or any right, title, interest or claim of any kind (“Claim”)
to, or to any monies in, the Trust Account, and hereby irrevocably waives any Claim to, or to any monies in, the Trust Account that it
may have now or in the future, except for redemption and liquidation rights, if any, the Purchaser may have in respect of any Public Shares
held by it. In the event the Purchaser has any Claim against the Company under this Agreement, the Purchaser shall not pursue such Claim
against the Trust Account or against the property or any monies in the Trust Account, except for redemption and liquidation rights, if
any, the Purchaser may have in respect of any Public Shares held by it.

 

    	 	9	 

     

    

  

(b) No Short Sales.
The Purchaser hereby agrees that neither it, nor any person or entity acting on its behalf or pursuant to any understanding with it,
will engage in any Short Sales with respect to securities of the Company prior to the Business Combination Closing. For purposes of this
Section 4(b), “Short Sales” shall include, without limitation, all “short sales” as defined in
Rule 200 promulgated under Regulation SHO under the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
and all types of direct and indirect stock pledges (other than pledges in the ordinary course of business as part of prime brokerage
arrangements), forward sale contracts, options, puts, calls, swaps and similar arrangements (including on a total return basis), and
sales and other transactions through non-U.S. broker dealers or foreign regulated brokers.

 

(c) Allocation Notice.
The Purchaser shall deliver the Allocation Notice to the Company immediately upon the allocation to this Agreement of capital which has
been committed to the Purchaser (in accordance with all binding obligations of the Purchaser), which in no event shall be later than
five (5) Business Days prior to such time as any definitive agreement with respect to a Business Combination is executed by the Company.

 

5. Additional
Agreements of the Company.

 

(a) No Material Non-Public
Information. The Company agrees that no information provided to the Purchaser in connection with this Agreement will, upon the IPO
Closing, constitute material non-public information of the Company.

 

(b) Nasdaq Listing.
The Company will use commercially reasonable efforts to effect and maintain the listing of the Ordinary Shares on The Nasdaq Capital
Market (or another national securities exchange).

 

(c) No Amendments to
the Articles. The amended and restated memorandum and articles of association of the Company will be in substantially the form attached
to the Registration Statement and will not be amended in any material respect prior to the IPO Closing without the Purchaser’s
prior written consent.

 

6. FPS
Closing Conditions.

 

(a) The
obligation of the Purchaser to purchase the Forward Purchase Securities at the FPS Closing under this Agreement shall be subject to the
fulfillment, at or prior to the FPS Closing of each of the following conditions, any of which, to the extent permitted by applicable laws,
may be waived by the Purchaser:

 

(i) The
Business Combination shall be consummated substantially concurrently with, and immediately following, the purchase of the Forward Purchase
Securities;

 

(ii) The
Company shall have delivered to such Purchaser a certificate evidencing the Company’s good standing as a Cayman Islands exempted
company, as of a date within ten (10) Business Days of the Closing Date;

 

(iii) The
representations and warranties of the Company set forth in Section 3 of this Agreement shall have been true and correct as of the
date hereof and shall be true and correct as of the FPS Closing, as applicable, with the same effect as though such representations and
warranties had been made on and as of such date (other than any such representation or warranty that is made by its terms as of a specified
date, which shall be true and correct as of such specified date), except where the failure to be so true and correct would not have a
material adverse effect on the Company or its ability to consummate the transactions contemplated by this Agreement;

 

    	 	10	 

     

    

  

(iv) The
Company shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by
this Agreement to be performed, satisfied or complied with by the Company at or prior to the FPS Closing; and

 

(v) No
order, writ, judgment, injunction, decree, determination, or award shall have been entered or threatened by or with any governmental,
regulatory, or administrative authority or any court, tribunal, or judicial, or arbitral body, and no other legal restraint or prohibition
shall be in effect or threatened, preventing the purchase by the Purchaser of the Forward Purchase Securities.

 

(b) The
obligation of the Company to sell the Forward Purchase Securities at the FPS Closing under this Agreement shall be subject to the fulfillment,
at or prior to the FPS Closing of each of the following conditions, any of which, to the extent permitted by applicable laws, may be waived
by the Company:

 

(i) The
Business Combination shall be consummated substantially concurrently with, and immediately following, the purchase of the Forward Purchase
Securities;

 

(ii) The
representations and warranties of the Purchaser set forth in Section 2 of this Agreement shall have been true and correct as of
the date hereof and shall be true and correct as of the FPS Closing, as applicable, with the same effect as though such representations
and warranties had been made on and as of such date (other than any such representation or warranty that is made by its terms as of a
specified date, which shall be true and correct as of such specified date), except where the failure to be so true and correct would not
have a material adverse effect on the Purchaser or its ability to consummate the transactions contemplated by this Agreement;

 

(iii) The
Purchaser shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required
by this Agreement to be performed, satisfied or complied with by the Purchaser at or prior to the FPS Closing; and

 

(iv) No
order, writ, judgment, injunction, decree, determination, or award shall have been entered or threatened by or with any governmental,
regulatory, or administrative authority or any court, tribunal, or judicial, or arbitral body, and no other legal restraint or prohibition
shall be in effect or threatened, preventing the purchase by the Purchaser of the Forward Purchase Securities.

 

7. Termination.
This Agreement may be terminated at any time prior to the FPS Closing:

 

(a) by
mutual written consent of the Company and the Purchaser; or

 

(b) automatically:

 

(i) if
the IPO is not consummated on or prior to twelve months from the date of this Agreement; or

 

    	 	11	 

     

    

  

(ii) if
the Business Combination is not consummated within twenty-four (24) months from the IPO Closing, or such later date as may be approved
by the Company’s shareholders in accordance with the Articles.

 

In the event of any termination
of this Agreement pursuant to this Section 7, the FPS Purchase Price (and interest thereon, if any), if previously paid, and all
Purchaser’s funds paid in connection herewith shall be promptly returned to the Purchaser in accordance with written instructions
provided by the Purchaser to the Company, and thereafter this Agreement shall forthwith become null and void and have no effect, without
any liability on the part of the Purchaser or the Company and their respective directors, officers, employees, partners, managers, members,
or shareholders and all rights and obligations of each party shall cease; provided, however, that nothing contained in this
Section 7 shall relieve either party from liabilities or damages arising out of any fraud or willful breach by such party of any
of its representations, warranties, covenants or agreements contained in this Agreement. Section 4(a) shall survive termination
of this Agreement.

 

8. General
Provisions.

 

(a) Notices. All
notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon
the earlier of actual receipt, or (i) hand delivery to the party to be notified, (ii) when sent, if sent by electronic mail during normal
business hours of the recipient, and if not sent during normal business hours, then on the recipient’s next Business Day or (iii)
one (1) Business Day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next Business Day delivery,
with written verification of receipt. All communications sent to the Company shall be sent to: Orion Acquisition Corp., 645 Fifth Avenue,
21st Floor, New York, New York 10022, Attn: Marcello Liguori with a copies to the Company’s counsel at: Kirkland & Ellis LLP,
601 Lexington Avenue, New York, New York 10022, Attn: Christian O. Nagler and Kirkland & Ellis LLP, 609 Main Street, Houston,
TX 77002, Attn: Debbie P. Yee, P.C., email: debbie.yee@kirkland.com, fax: (713) 836-3601.

 

All communications to the
Purchaser shall be sent to the Purchaser’s address as set forth on the signature page hereof, or to such e-mail address, facsimile
number (if any) or address as subsequently modified by written notice given in accordance with this Section 8(a).

 

(b) No Finder’s
Fees. Other than fees payable to the underwriters of the IPO or any other investment bank or financial advisor who assists the Company
in sourcing targets for a Business Combination, which fees shall be the responsibility of the Company, each party represents that it
neither is nor will be obligated for any finder’s fee or commission in connection with this transaction. The Purchaser agrees to
indemnify and to hold harmless the Company from any liability for any commission or compensation in the nature of a finder’s or
broker’s fee arising out of this transaction (and the costs and expenses of defending against such liability or asserted liability)
for which the Purchaser or any of its officers, employees or representatives is responsible. The Company agrees to indemnify and hold
harmless the Purchaser from any liability for any commission or compensation in the nature of a finder’s or broker’s fee
arising out of this transaction (and the costs and expenses of defending against such liability or asserted liability) for which the
Company or any of its officers, employees or representatives is responsible.

 

    	 	12	 

     

    

  

(c) Survival of Representations
and Warranties. All of the representations and warranties contained herein shall survive the FPS Closing.

 

(d) Entire Agreement.
This Agreement, together with any documents, instruments and writings that are delivered pursuant hereto or referenced herein, constitutes
the entire agreement and understanding of the parties hereto in respect of the subject matter hereof and supersedes all prior understandings,
agreements, or representations by or among the parties hereto, written or oral, to the extent they relate in any way to the subject matter
hereof or the transactions contemplated hereby.

 

(e) Successors.
All of the terms, agreements, covenants, representations, warranties, and conditions of this Agreement are binding upon, and inure to
the benefit of and are enforceable by, the parties hereto and their respective successors. Nothing in this Agreement, express or implied,
is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations
or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

 

(f) Assignments.
Except as otherwise specifically provided herein, no party hereto may assign either this Agreement or any of its rights, interests, or
obligations hereunder without the prior written consent of the other party. Notwithstanding the foregoing, the Purchaser may assign and
delegate all or a portion of its rights and obligations to purchase the Forward Purchase Securities to one or more other persons upon
the consent of the Company (which consent shall not be unreasonably conditioned, withheld or delayed); provided, however,
that no consent of the Company shall be required if such assignment or delegation is to an affiliate of the Purchaser; provided,
further, that no such assignment or delegation shall relieve the Purchaser of its obligations hereunder (including its obligation
to purchase the Number of Forward Purchase Shares and the Number of Forward Purchase Warrants hereunder) and the Company shall be entitled
to pursue all rights and remedies against the Purchaser subject to the terms and conditions hereof.

 

(g) Counterparts.
This Agreement may be executed in two or more counterparts, each of which will be deemed an original but all of which together will constitute
one and the same instrument.

 

(h) Headings. The
section headings contained in this Agreement are inserted for convenience only and will not affect in any way the meaning or interpretation
of this Agreement.

 

(i) Governing Law.
This Agreement, the entire relationship of the parties hereto, and any dispute between the parties (whether grounded in contract, tort,
statute, law or equity) shall be governed by, construed in accordance with, and interpreted pursuant to the laws of the State of New
York, without giving effect to its choice of laws principles.

 

    	 	13	 

     

    

  

(j) Jurisdiction.
The parties (i) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of New York and to the jurisdiction
of the United States District Court for the Southern District of New York for the purpose of any suit, action or other proceeding arising
out of or based upon this Agreement, (ii) agree not to commence any suit, action or other proceeding arising out of or based upon this
Agreement except in state courts of New York or the United States District Court for the Southern District of New York, and (iii) hereby
waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that
it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or
execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding
is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court.

 

(k) WAIVER OF JURY
TRIAL. THE PARTIES HERETO HEREBY WAIVE ANY RIGHT TO A JURY TRIAL IN CONNECTION WITH ANY LITIGATION PURSUANT TO THIS AGREEMENT AND
THE TRANSACTIONS CONTEMPLATED HEREBY.

 

(l) Amendments.
This Agreement may not be amended, modified or waived as to any particular provision, except with the prior written consent of the Company
and the Purchaser.

 

(m) Severability.
The provisions of this Agreement will be deemed severable and the invalidity or unenforceability of any provision will not affect the
validity or enforceability of the other provisions hereof; provided that if any provision of this Agreement, as applied to any party
hereto or to any circumstance, is adjudged by a governmental authority, arbitrator, or mediator not to be enforceable in accordance with
its terms, the parties hereto agree that the governmental authority, arbitrator, or mediator making such determination will have the
power to modify the provision in a manner consistent with its objectives such that it is enforceable, and/or to delete specific words
or phrases, and in its reduced form, such provision will then be enforceable and will be enforced.

 

(n) Expenses. Each
of the Company and the Purchaser will be responsible for payment of its own costs and expenses incurred in connection with the preparation,
execution and performance of this Agreement and the consummation of the transactions contemplated hereby, including all fees and expenses
of agents, representatives, financial advisors, legal counsel and accountants. The Company shall be responsible for the fees of its transfer
agent; stamp taxes and all of The Depository Trust Company’s fees associated with the issuance and resale of the Forward Purchase
Securities and the securities issuable upon conversion or exercise of the Forward Purchase Securities.

 

    	 	14	 

     

    

  

(o) Construction.
The parties hereto have participated jointly in the negotiation and drafting of this Agreement. If an ambiguity or question of intent
or interpretation arises, this Agreement will be construed as if drafted jointly by the parties hereto and no presumption or burden of
proof will arise favoring or disfavoring any party hereto because of the authorship of any provision of this Agreement. Any reference
to any federal, state, local, or foreign law will be deemed also to refer to law as amended and all rules and regulations promulgated
thereunder, unless the context requires otherwise. The words “include,” “includes,” and “including”
will be deemed to be followed by “without limitation.” Pronouns in masculine, feminine, and neuter genders will be
construed to include any other gender, and words in the singular form will be construed to include the plural and vice versa, unless
the context otherwise requires. The words “this Agreement,” “herein,” “hereof,”
“hereby,” “hereunder,” and words of similar import refer to this Agreement as a whole and not to
any particular subdivision unless expressly so limited. The parties hereto intend that each representation, warranty, and covenant contained
herein will have independent significance. If any party hereto has breached any representation, warranty, or covenant contained herein
in any respect, the fact that there exists another representation, warranty or covenant relating to the same subject matter (regardless
of the relative levels of specificity) which such party hereto has not breached will not detract from or mitigate the fact that such
party hereto is in breach of the first representation, warranty, or covenant.

 

(p) Waiver. No
waiver by any party hereto of any default, misrepresentation, or breach of warranty or covenant hereunder, whether intentional or not,
may be deemed to extend to any prior or subsequent default, misrepresentation, or breach of warranty or covenant hereunder or affect
in any way any rights arising because of any prior or subsequent occurrence.

 

(q) Specific Performance.
The Purchaser agrees that irreparable damage may occur in the event any provision of this Agreement was not performed by the Purchaser
in accordance with the terms hereof and that the Company shall be entitled to specific performance of the terms hereof, in addition to
any other remedy at law or equity.

 

[Signature Page Follows] 

 

    	 	15	 

     

    

 

IN WITNESS WHEREOF,
the undersigned have executed this Agreement to be effective as of the date first set forth above.

 

	PURCHASER:	 
	 	 
	Orion Sponsor Holdings, LLC	 
	 	 	 
	By:	/s/ Marcello Liguori	 
	Name: 	Marcello Liguori	
	Title:	Member	 
	 	 	 
	Address for Notices:	 
	 	 
	645 Fifth Avenue, 21st Floor	 
	New York, New York 10022	 
	Attn:	Marcello Liguori	 
	Email:	mliguori@msdpartners.com	 
	 	 	 
	COMPANY:	 
	 	 
	Orion Biotech Opportunities Corp.	 
	 	 	 
	By:	/s/ Mark Kayal	 
	Name:	Mark Kayal	 
	Title:	Chief Financial Officer & Secretary	 

 

with copies (which shall not constitute notice) to:

 

Kirkland & Ellis LLP

601 Lexington Avenue

New York, New York 10022

Attention: Christian O. Nagler

 

and

 

Kirkland & Ellis LLP

609 Main Street Houston, Texas 77002

Attn:Debbie P. Yee, P.C.

Email:debbie.yee@kirkland.com

 

[Signature Page to Forward Purchase Agreement] 

 

     

     

    

 

[Exhibit A]

 

Registration Rights

 

1. Within
thirty (30) days after the Business Combination Closing, the Company shall use reasonable best efforts (i) to file a registration statement
on Form S-3 for a secondary offering (including any successor registration statement covering the resale of the Registrable Securities,
a “Resale Shelf”) of (x) the Ordinary Shares and Forward Purchase Warrants (and underlying Ordinary Shares)
comprising the Forward Purchase Securities and (y) any other equity security of the Company issued or issuable with respect to the securities
referred to in clause (x) by way of a share capitalization or share split or in connection with a combination of shares, recapitalization,
merger, consolidation or reorganization (collectively, for so long as such securities are held by the Purchaser or its assignees under
the Agreement (each, a “Holder”), the “Registrable Securities”) pursuant
to Rule 415 under the Securities Act; provided that if Form S-3 is unavailable for such a registration, the Company shall register
the resale of the Registrable Securities on another appropriate form and undertake to register the Registrable Securities on Form S-3
as soon as such form is available, (ii) to cause the Resale Shelf to be declared effective under the Securities Act promptly thereafter,
but in no event later than sixty (60) days after the initial filing of the Resale Shelf, and (iii) to maintain the effectiveness of such
Resale Shelf with respect to the Registrable Securities until the earliest of (A) the date on which such securities are no longer Registrable
Securities and (B) the date all of the Registrable Securities covered by the Resale Shelf can be sold publicly without restriction or
limitation under Rule 144 under the Securities Act and without the requirement to be in compliance with Rule 144(c)(1) under the Securities
Act.

 

2. The
Holders may, after the Resale Shelf becomes effective, deliver a written notice to the Company (the “Underwritten Offering
Notice”) specifying that the sale of some or all of the Registrable Securities subject to the Resale Shelf is intended
to be conducted through a firm commitment underwritten offering (an “Underwritten Offering”); provided,
however, that the Holders of Registrable Securities may not, without the Company’s prior written consent, (i) launch an Underwritten
Offering the anticipated gross proceeds of which shall be less than $5,000,000 (unless the Holders are proposing to sell all of their
remaining Registrable Securities), (ii) launch more than three Underwritten Offerings at the request of the Holders within any three-hundred
sixty-five (365) day-period or (iii) launch an Underwritten Offering within the period commencing fourteen (14) days prior to and ending
two (2) days following the Company’s scheduled earnings release date for any fiscal quarter or year. In the event of an Underwritten
Offering, the Holders representing a majority-in-interest of the Registrable Securities to be included in such Underwritten Offering shall
select the managing underwriter(s) for the Underwritten Offering; provided that the choice of such managing underwriter(s) shall
be subject to the consent of the Company, which is not to be unreasonably withheld, conditioned or delayed. If the underwriter(s) for
any Underwritten Offering pursuant to this paragraph 2 of this Exhibit A (each, a “Secondary Offering”)
advise the Company and the Holders that, in their good faith opinion, marketing factors require a limitation on the number of securities
that may be included in such Secondary Offering, the number of securities to be so included shall be allocated as follows: (i) first,
to the Holders that have requested to participate in such Secondary Offering, allocated pro rata among such Holders on the basis of the
percentage of the Registrable Securities requested to be included in such Secondary Offering by such Holders, and (ii) second, to the
holders of any other securities of the Company that have been requested to be so included.

 

    	 	A-1	 

     

    

  

3. Upon
receipt of prior written notice by any Holder that they intend to effect a sale of Registrable Securities held by them as are then registered
pursuant to the Resale Shelf, the Company shall use its reasonable best efforts to cooperate in such sale (whether or not such sale constitutes
an Underwritten Offering), including by amending or supplementing the prospectus related to such Resale Shelf as may be reasonably requested
by such Holder for so long as such Holder holds Registrable Securities.

 

4. In
the event the Company is prohibited by applicable rule, regulation or interpretation by the staff (the “Staff”)
of the SEC from registering all of the Registrable Securities on the Resale Shelf or the Staff requires that any Holder be specifically
identified as an “underwriter” in order to permit such registration statement to become effective, and such Holder does not
consent in writing to being so named as an underwriter in such registration statement, the number of Registrable Securities to be registered
on the Resale Shelf will be reduced on a pro rata basis among all Holders to be so included, unless otherwise required by the Staff, so
that the number of Registrable Securities to be registered is permitted by the Staff and such Holder is not required to be named as an
“underwriter”; provided, that any Registrable Securities not registered due to this paragraph 4 shall thereafter as
soon as allowed by the SEC guidance be registered to the extent the prohibition no longer is applicable.

 

5. If
at any time the Company proposes to file a registration statement (a “Registration Statement”) on its
own behalf, or on behalf of any other Persons who have registration rights (“Other Holders”), relating
to an Underwritten Offering of ordinary shares (a “Company Offering”), then the Company will provide
the Holders with notice in writing (an “Offer Notice”) at least three (3) Business Days prior to such
filing, which Offer Notice will offer to include in the Registration Statement the Registrable Securities held by each Holder (the “Piggyback
Securities”). Within three (3) Business Days after receiving the Offer Notice, each Holder may make a written request
(a “Piggyback Request”) to the Company to include some or all of such Holder’s Registrable Securities
in the Registration Statement. If the underwriter(s) for any Company Offering advise the Company that, in their good faith opinion, marketing
factors require a limitation on the number of securities that may be included in the Company Offering, the number of securities to be
so included shall be allocated as follows: (i) first, to the Company and the Other Holders, if any; and (ii) second, to the Holders and
any other holders of similar piggyback rights, based pro rata on the value of the securities requested to be sold in such Company Offering
by each requesting holder. By written notice delivered to the Company, any Holder (an “Opting-Out Holder”) may
elect to waive its right to participate in Company Offerings (“Registration Opt-Out”) until such time as such
written notice is rescinded in writing. During such time as a Registration Opt-Out is in effect: (x) the Opting-Out Holder shall not receive
notices of any proposed Company Offering and (y) shall not be entitled to participate in any such Company Offering.

 

6. In
connection with any Underwritten Offering, the Company shall enter into such customary agreements and take all such other actions in connection
therewith (including those requested by Holders representing a majority-in-interest of the Registrable Securities to be included in such
Underwritten Offering) in order to facilitate the disposition of such Registrable Securities as are reasonably necessary or required,
and in such connection enter into a customary underwriting agreement that provides for customary opinions, comfort letters and officer’s
certificates and other customary deliverables.

 

    	 	A-2	 

     

    

  

7. The
Company shall pay all fees and expenses incident to the performance of or compliance with its obligation to prepare, file and maintain
the Resale Shelf (including the fees of its counsel and accountants). The Company shall also pay all Registration Expenses. For purposes
of this paragraph 7, “Registration Expenses” shall mean the out-of-pocket expenses of any Secondary Offering
and any Company Offering, including, without limitation, the following: (i) all registration and filing fees (including fees with respect
to filings required to be made with FINRA and any securities exchange on which the Registrable Securities are then listed); (ii) fees
and expenses of compliance with securities or blue sky laws (including reasonable fees and disbursements of counsel for the underwriters
in connection with blue sky qualifications of the Registrable Securities); (iii) printing, messenger, telephone and delivery expenses;
(iv) reasonable fees and disbursements of counsel for the Company; (v) reasonable fees and disbursements of all independent registered
public accountants of the Company; and (vi) reasonable fees and expenses of one (1) legal counsel selected by Holders representing a majority-in-interest
of the Registrable Securities participating in any such Secondary Offering, but shall not include any incremental selling expenses relating
to the sale of Registrable Securities, such as underwriters’ commissions and discounts, brokerage fees and underwriter marketing
costs; and provided that the Company shall only be responsible for expenses under clause (vi) with respect to two Secondary Offerings
in any consecutive three-hundred sixty-five (365) day-period.

 

8. The
Company may suspend the use of a prospectus included in the Resale Shelf by furnishing to the Holders a written notice (“Suspension
Notice”) stating that in the good faith judgment of the Company, it would be either (i) prohibited by the Company’s
insider trading policy (as if the Holders were covered by such policy) or (ii) materially detrimental to the Company and its shareholders
for such prospectus to be used at such time. The Company’s right to suspend the use of such prospectus under clause (ii) of the
preceding sentence may be exercised for a period of not more than ninety (90) days after the date of such notice to the Holders; provided
that such period may be extended for an additional thirty (30) days with the consent of Holders representing a majority-in-interest of
the Registrable Securities, which consent shall not be unreasonably withheld; provided further, that such right to suspend the
use of a prospectus shall be exercised by the Company not more than once in any twelve (12) month period. The Holders shall not effect
any sales of Registrable Securities pursuant to the Resale Shelf at any time after they have received a Suspension Notice from the Company
and prior to receipt of an End of Suspension Notice (as defined below). The Holders may recommence effecting sales of the Registrable
Securities pursuant to the Resale Shelf following further written notice to such effect (an “End of Suspension Notice”)
from the Company to the Holders. The Company shall act in good faith to permit any suspension period contemplated by this paragraph 8
to be concluded as promptly as reasonably practicable.

 

9. The
Holders agree that, except as required by applicable law, the Holders shall treat as confidential the receipt of any Suspension Notice
(provided that in no event shall such notice contain any material non-public information of the Company) hereunder and shall not disclose
or use the information contained in such Suspension Notice without the prior written consent of the Company until such time as the information
contained therein is or becomes public, other than as a result of disclosure by a Holder of Registrable Securities in breach of the terms
of this Agreement.

 

    	 	A-3	 

     

    

  

10. The
Company agrees to indemnify, to the extent permitted by law, each Holder of Registrable Securities, its officers and directors and each
person who controls such Holder (within the meaning of the Securities Act) against all losses, claims, damages, liabilities and expenses
(including attorneys’ fees) caused by any untrue or alleged untrue statement of material fact contained in the Resale Shelf (or
any amendment or supplement thereto), the related prospectus or any amendment thereof or supplement thereto or any omission or alleged
omission of a material fact required to be stated therein or necessary to make the statements therein not misleading, except insofar as
the same are caused by or contained in any information furnished in writing to the Company by such Holder expressly for use therein.

 

11. The
Company’s obligation under paragraph 1 of this Exhibit A is subject to each Holder furnishing to the Company in writing such information
as the Company reasonably requests for use in connection with the Resale Shelf, the related prospectus, or any amendment or supplement
thereto. Each Holder shall indemnify the Company, its officers, directors, managers, employees, agents and representatives, and each person
who controls the Company (within the meaning of the Securities Act) against any losses, claims, damages, liabilities and expenses resulting
from any untrue statement or alleged untrue statement of material fact contained in the Resale Shelf, the related prospectus, or any amendment
or supplement thereto or any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements
therein not misleading, but only to the extent that such untrue statement or omission is contained in any information so furnished in
writing by such Holder expressly for inclusion in such Resale Shelf, related prospectus or amendment or supplement thereto, as applicable;
provided that the obligation to indemnify shall be individual, not joint and several, and shall be limited to the net amount of proceeds
received by the applicable Holder from the sale of Registrable Securities pursuant to the Resale Shelf.

 

12. The
Company shall cooperate with the Holders, to the extent the Registrable Securities become freely tradable, to facilitate the timely preparation
and delivery of certificates (not bearing any restrictive legend) representing the Registrable Securities to be offered pursuant to a
Resale Shelf and enable such certificates to be in such denominations or amounts, as the case may be, as the Holders may reasonably request
and registered in such names as each Holder may request.

 

13. If
requested by Holders representing a majority-in-interest of the Registrable Securities, the Company shall as soon as practicable, subject
to any Suspension Notice, (i) incorporate in a prospectus supplement or post-effective amendment such information as each Holder reasonably
requests to be included therein relating to the sale and distribution of Registrable Securities, including, without limitation, information
with respect to the number of Registrable Securities being offered or sold, the purchase price being paid therefor and any other terms
of the offering of the Registrable Securities to be sold in such offering; (ii) make all required filings of such prospectus supplement
or post-effective amendment after being notified of the matters to be incorporated in such prospectus supplement or post-effective amendment;
and (iii) supplement or make amendments to any Registration Statement if reasonably requested by Holders representing a majority-in-interest
of the Registrable Securities.

 

14. As
long as Registrable Securities are outstanding, the Company, at all times while it shall be reporting under the Exchange Act, covenants
to file timely (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed
by the Company after the date hereof pursuant to Sections 13(a) or 15(d) of the Exchange Act, and to promptly furnish the Holders with
true and complete copies of all such filings, unless filed through the SEC’s EDGAR system. The Company further covenants that it
shall take such further action as the Holders may reasonably request, all to the extent required from time to time, to enable the Holders
to sell the Ordinary Shares and Forward Purchase Warrants held by the Holders without registration under the Securities Act within the
limitation of the exemptions provided by Rule 144 promulgated under the Securities Act, including providing any legal opinions, to the
extent such exemption is available to the Purchaser at such time. Upon the request of any Holder, the Company shall deliver to such Holder
a written certification of a duly authorized officer as to whether it has complied with such requirements.

 

 

A-4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}]]